Table 2 Empiric therapies and proportion of unfavorable outcomes on both groups of cefmetazole (CMZ) and carbapenems (CPs)
From: Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
CMZ group | CPs group | ||||||
|---|---|---|---|---|---|---|---|
Empiric therapy | Number | Unfavorable outcomes | Empiric therapy | Number | Unfavorable outcomes | ||
Empiric therapy effective against the causative organisms | CPs | 7 | 1:died | Empiric therapy effective against the causative organisms | CPs | 27 | 3:died, 2:relapsed |
tazobactam/piperacillin | 4 | none | |||||
CMZ | 2 | ||||||
Empiric therapy ineffective against the causative organisms | cefepime | 4 | none | Empiric therapy ineffective against the causative organisms | cefazolin | 5 | 1:died |
ceftriaxone | 3 | ceftriaxone | 4 | 1:died | |||
sulbactam/ampicillin | 3 | sulbactam/cefoperazone | 3 | none | |||
others | 3 | Others | 2 | ||||